Surgical Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis

2013 ◽  
Vol 38 (2) ◽  
pp. 490-496 ◽  
Author(s):  
Kenneth S. H. Chok ◽  
Tan To Cheung ◽  
See Ching Chan ◽  
Ronnie T. P. Poon ◽  
Sheung Tat Fan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Surgical Outcomes ◽  
Portal Vein Tumor Thrombosis ◽  
Tumor Thrombosis

scholarly journals Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis

2018 ◽  
Vol Volume 10 ◽  
pp. 4719-4726 ◽  
Author(s):  
Wei-Fu Lv ◽  
Kai-Cai Liu ◽  
Dong Lu ◽  
Chun-Ze Zhou ◽  
De-Lei Cheng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Transarterial Chemoembolization ◽  
Portal Vein Tumor Thrombosis ◽  
Tumor Thrombosis

Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis

Brachytherapy ◽  
2019 ◽  
Vol 18 (2) ◽  
pp. 233-239 ◽  
Author(s):  
Junqing Lin ◽  
Han Jiang ◽  
Weizhu Yang ◽  
Na Jiang ◽  
Qubin Zheng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Predictive Factors ◽  
Portal Vein Tumor Thrombosis ◽  
Tumor Thrombosis ◽  
Iodine 125

scholarly journals Observation of Stereotactic Radiosurgery (Cyberknife) on Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

2018 ◽  
Vol 2 (4) ◽  
Author(s):  
Yang Tang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Rate ◽  
Portal Vein ◽  
Stereotactic Radiosurgery ◽  
Cox Proportional Hazards Model ◽  
Cumulative Survival Rate ◽  
Portal Vein Tumor Thrombosis ◽  
Cumulative Survival ◽  
Tumor Thrombosis ◽  
Stable Conditions

The purpose of the study was to analyze the clinical effect of stereotactic radiosurgery (SRS) (Cyberknife) on hepatocellular carcinoma with portal vein tumor thrombosis (HCC-PVTT). Data from 50 patients with HCC-PVTT who received Cyberknife from August 2013 to April 2016 was collected for efficacy analysis. Moreover, survival correlation was evaluated by Cox proportionalhazards model. The total effective rate in 1–3 months after treatment was 64.00%, including 7 cases in complete remission, 12 cases in partial remission, 13 cases in stable conditions, and 18 cases with enlargement; a 4–24-months follow-up (with an average of 11.58 ± 2.58 months) showed that median survival, 1-year cumulative survival rate, and 2-year cumulative survival rate were, respectively, 11.86 ± 1.79 months, 48.00%, and 20.00%. Moreover, the Cox proportional-hazards model indicates that it was with no correlation between lesion diameter, classification of liver function, pre-operative alphafetoprotein, types of hepatitis, number of tumors, ascites, types of tumor emboli, total dose, and survival rate. SRS is effective for HCC-PVTT and serves as an ideal treatment clinically to help preserve patients’ lives, which is worthy of clinical promotion and application.

Sign in / Sign up

Export Citation Format

Share Document